Article
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Lung - 1 Oct 2013
Locatelli-Sanchez Myriam, Couraud Sébastien, Arpin Dominique, Riou Robert, Bringuier Pierre-Paul, Souquet Pierre-Jean
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR)-targeting therapies dramatically modified the prognosis of stage 4 non-small-cell lung cancer. Sensitizing EGFR mutations are the best efficacy factor of these treatments. In 2006, the French National Cancer Institute launched a network of 28 centers for EGFR molecular analysis in routine practice. The aim of this retrospective study was to describe the results...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
